Examines a bioinformatics-derived glycolysis gene signature in lung adenocarcinoma and its association with prognosis, drug resistance, and treatment sensitivity predictions.
Key Takeaways
- Patients stratified by glycolysis-related risk scores exhibited significantly distinct survival outcomes
- Transcriptomic and clinical data for LUAD were obtained from the TCGA and GEO databases
- Samples were retained if they met the following criteria